Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.43 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28265738 | 0.89 | IDO1 (0.48) | IDO1NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL706436 | 0.84 | MAPT (0.46) | IDO1NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL28327748 | 0.84 | IDO1 (0.43) | IDO1NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL28270530 | 0.83 | MAPK13 (0.54) | IDO1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL453506 | 0.82 | KDM4E (0.48) | IDO1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL28326465 | 0.80 | MAPK13 (0.50) | IDO1SMN1; SMN2TP53MAPTTDO2 | |
| SCHEMBL28270660 | 0.80 | IDO1 (0.58) | IDO1NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL23294716 | 0.76 | NPC1 (0.46) | IDO1NPC1RAB9ATSHRSMN1; SMN2 | |
| Phenol SCHEMBL28258861 | 0.74 | RPS6KA3 (0.45) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL17283565 | 0.72 | MAPK14 (0.45) | IDO1NPC1RAB9ATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8273709-B2 | Triazole-containing macrocyclic HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273709-B2 | Triazole-containing macrocyclic HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009117594-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090191151-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191151-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009079353-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191151-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | TMPRSS4, SPINT2, PRSS1 | IDO1 986/4885NPC1 246/4885RAB9A 3217/4885 |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, SPINT2, CTSV | IDO1 1617/4885NPC1 27/4885RAB9A 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.